

# RESULTS PRESENTATION

## Q2 2025

AUGUST 25, 2025

(\*) Due to rounding, the figures presented throughout this report may not match the totals shown, and the percentages may not accurately reflect the absolute figures.

This document may contain statements with future estimates regarding the financial condition, results of operations and business of the company, and certain plans and objectives of the company. Future estimates are merely statements of intent, beliefs or expectations of Molymet and its management regarding the future results of the company. By their nature, these statements involve risks and uncertainties because they relate to circumstances that will occur in the future.





# MAIN RESULTS

Q2 2025

REVENUE  
**US\$ 1,149 MM**  
(+9% vs Q2-24)

EBITDA  
**US\$ 79 MM**  
(+3% vs Q2-24)

NET INCOME  
**US\$ 44 MM**  
(+24% vs Q2-24)


NET DEBT  
**US\$ 353 MM**  
(+23% vs Q2-24)




# MAIN RESULTS

Q2 2025


REVENUE  
US\$ 1,149 MM  
(+9% vs Q2 2024)




Mo Own Sales  
US\$ 1,082 MM



Mo Tolling  
US\$ 16 MM



By-products  
US\$ 51 MM




Sales volume of rhenium products reached 58k pounds at the end of June 2025.  
-3% vs Q2-2024



# MAIN RESULTS


Q2 2025

EBITDA  
**US\$ 79 MM**  
(+3% vs Q2-24)




Own Sales (US\$ MM).  
Tolling (US\$ MM).  
By-products (US\$ MM).


Other operation costs and expenses  
**US\$ 41 MM**  
(+7% vs Q2-24)



Net Financial Expense  
**US\$ 10 MM**  
(+29% vs Q2-24)




UTILIDAD NETA  
**US\$ 44 MM**  
(+24% vs Q2-24)






# MOLYBDENUM PRICE EVOLUTION


Año	Precio promedio (US\$/Lb)
Q2 2024	22
Q3 2024	22
Q4 2024	22
2024	21
Q1 2025	21
Q2 2025	21



Operating Cash Flow  
**US\$ -5 MM**  
(-104% vs Q2-24)



CAPEX\*  
**US\$ 15 MM**  
(-26% vs Q2-24)



\*VAT excluded.




# DEBT SITUATION

## NET FINANCIAL DEBT

**US\$ 353 MM**

(+23% vs Q4-24)



\* Book Debt: Current Financial Liabilities + Non-Current Financial Liabilities.

\*\* Book Cash: Cash and Cash Equivalents + Current Financial Assets + Non-Current Financial Assets.

## FINANCIAL DEBT PROFILE


### March 2025

Debt refinancing for **US\$ 124 MM**.

There are no relevant maturities until 2028.

### Financial Debt Maturity Profile\*

As of June 30, 2025 – US\$ MM




\* USD amounts include debt hedging derivatives.




# COVENANTS FOLLOW UP

RESULTS Q2 2025




- Molymet modified the "EBITDA / Net Financial Expenses" covenant for its bonds issued in Mexico. This change will be effective as of the end of **September 2025**.

\*For this covenant, a waiver was maintained until the close of December 2024, inclusive.



\*(Consolidated liabilities – (Inventories - Accounts payable of molybdenum) / Equity.





# MATERIAL EVENTS

## Q2 2025

**March  
19**

-----  
Prepayment  
of bond  
**MOLYMET 21-2**  
for approximately  
**US\$ 121 million.**  
-----

**March  
26**

-----  
Issuance of bond  
**MOLYMET 25**  
for approximately  
**US\$ 124 million.**  
-----

**April  
23**

-----  
**Annual  
Shareholder's  
Meeting**  
-----

Approval of the  
payment of  
dividends for  
approximately  
**US\$ 33 million.**

**Abril  
30**

-----  
Resignation of  
**Mr. Raúl Álamos**  
to the Company's  
**Director's Board.**  
-----

**May  
19**

-----  
Incorporation of  
**Mr. Jorge Méndez**  
to the Company's  
**Director's Board.**  
-----



